Needham Upgrades Rocket Pharmaceuticals to Buy, Announces $9 Price Target

Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development

Wedbush Reiterates Outperform on Rocket Pharmaceuticals, Maintains $15 Price Target

Wedbush analyst Yun Zhong reiterates Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and maintains $15 price target.

8-K filing — ROCKET PHARMACEUTICALS, INC. (RCKT)

Filed: 2026-10-06 AccNo: 0001140361-26-038818 Size: 10 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Rocket Pharmaceuticals Announces Up To $150M Credit Facility With Hercules Capital, $35M Received At Closing; Expects Cash Runway Into Q3 2028